Breaking News Instant updates and real-time market news.

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56

Pfizer presents overall survival data from PALOMA-3 trial of Ibrance

Pfizer announced detailed overall survival data from the PALOMA-3 trial, which evaluated Ibrance in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer whose disease progressed on or after prior endocrine therapy. In the study, there was a numerical improvement in OS of nearly seven months with Ibranceplus fulvestrant compared to placebo plus fulvestrant, although this difference did not reach the prespecified threshold for statistical significance versus 28.0 months. The difference in median OS demonstrated in this analysis is consistent with the improvement previously demonstrated for the primary endpoint of median progression-free survival. In the updated PFS analysis for this study, the combination of Ibrance plus fulvestrant showed a statistically significant and clinically meaningful 6.6-month mPFS improvement compared to placebo plus fulvestrant. Overall survival is a secondary endpoint of PALOMA-3, and the trial design was not optimized to detect a statistically significant difference in OS. At the time of this analysis, follow-up was 44.8 months and approximately 60% of events had occurred in the 521 patients enrolled. Patients on both arms received up to 10 lines of post-progression treatment. The trend toward OS favoring the Ibrance plus fulvestrant arm was observed across most subgroups, with hazard ratios consistent with the overall population. In addition, for the overall population, the difference in OS was associated with prolonged time from randomization to first use of chemotherapy post-progression, an exploratory endpoint. Median time to chemotherapy was 17.6 months for patients who received Ibrance plus fulvestrant, twice that observed in patients who received placebo plus fulvestrant. The most common adverse reactions in PALOMA-3 included neutropenia, leukopenia, infections, fatigue and nausea. No new safety signals observed with longer follow-up were identified as part of this final OS analysis.

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

PFE Pfizer
$44.50

0.48 (1.09%)

10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
10/01/18
JPMS
10/01/18
NO CHANGE
Target $46
JPMS
Overweight
Pfizer price target raised to $46 from $42 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Pfizer to $46 on a revisit of the company's story. The analyst sees a "meaningful shift" in the Pfizer narrative away from potential acquisitions to the company's organic growth prospects post the Lyrica patent expiration in 2019. While he expects the company's growth will slow in 2019/2020, he sees a "distinct re-acceleration" of sales and earnings growth for Pfizer in the 2021-2025 period. Schott believes shares of Pfizer can further re-rate if the Street gains further confidence in its "sustained topline growth and capital deployment opportunities." The analyst keeps an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

C

Citi

$70.08

0.61 (0.88%)

, FIS

FIS

$132.88

-1.54 (-1.15%)

08:25
09/19/19
09/19
08:25
09/19/19
08:25
Conference/Events
Securities Industry & Financial Markets Association to hold a conference »

Equity Market Structure…

C

Citi

$70.08

0.61 (0.88%)

FIS

FIS

$132.88

-1.54 (-1.15%)

GS

Goldman Sachs

$217.08

1.15 (0.53%)

MS

Morgan Stanley

$44.36

0.16 (0.36%)

NDAQ

Nasdaq

$102.59

-0.21 (-0.20%)

TROW

T. Rowe Price

$117.13

-0.85 (-0.72%)

UBS

UBS

$11.44

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 26

    Sep

  • 15

    Oct

  • 15

    Oct

  • 18

    Oct

  • 13

    Nov

STX

Seagate

$56.74

0.7 (1.25%)

08:25
09/19/19
09/19
08:25
09/19/19
08:25
Conference/Events
Seagate to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:24
09/19/19
09/19
08:24
09/19/19
08:24
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAX

Baxter

$87.48

-0.135 (-0.15%)

, HRC

Hill-Rom

$104.08

0.46 (0.44%)

08:24
09/19/19
09/19
08:24
09/19/19
08:24
Conference/Events
KeyBanc to hold a field trip »

Chicago Field Trip…

BAX

Baxter

$87.48

-0.135 (-0.15%)

HRC

Hill-Rom

$104.08

0.46 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

  • 27

    Sep

  • 30

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 24

    Oct

$DJU

DJ Utility Average

$0.00

(0.00%)

08:24
09/19/19
09/19
08:24
09/19/19
08:24
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:24
09/19/19
09/19
08:24
09/19/19
08:24
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:24
09/19/19
09/19
08:24
09/19/19
08:24
Conference/Events
Deutsche Bank to hold a conference »

Australia Gold Corporate…

IYT

iShares Transportation Average

$190.85

-2.3 (-1.19%)

08:24
09/19/19
09/19
08:24
09/19/19
08:24
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$81.29

0.04 (0.05%)

08:23
09/19/19
09/19
08:23
09/19/19
08:23
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$61.94

-0.26 (-0.42%)

08:23
09/19/19
09/19
08:23
09/19/19
08:23
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:23
09/19/19
09/19
08:23
09/19/19
08:23
Conference/Events
CFTC Commissioner participates in a summit »

Commissioner Quintenz of…

XLY

Consumer Discretionary Sector SPDR

$122.53

-0.06 (-0.05%)

08:23
09/19/19
09/19
08:23
09/19/19
08:23
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$59.91

0.05 (0.08%)

08:23
09/19/19
09/19
08:23
09/19/19
08:23
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon CEO says working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

  • 25

    Oct

XLB

S&P Select Materials SPDR

$58.67

0.04 (0.07%)

08:23
09/19/19
09/19
08:23
09/19/19
08:23
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$63.83

0.28 (0.44%)

08:22
09/19/19
09/19
08:22
09/19/19
08:22
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$60.84

0.03 (0.05%)

08:22
09/19/19
09/19
08:22
09/19/19
08:22
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPN

Global Payments

$164.32

0.43 (0.26%)

08:22
09/19/19
09/19
08:22
09/19/19
08:22
Recommendations
Global Payments analyst commentary  »

We like Global Payments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 13

    Nov

XLV

Health Care Select Sector SPDR

$91.46

0.02 (0.02%)

08:22
09/19/19
09/19
08:22
09/19/19
08:22
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$156.51

-0.94 (-0.60%)

08:22
09/19/19
09/19
08:22
09/19/19
08:22
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$271.97

0.42 (0.15%)

08:21
09/19/19
09/19
08:21
09/19/19
08:21
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$301.10

0.16 (0.05%)

08:21
09/19/19
09/19
08:21
09/19/19
08:21
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$54.51

-0.52 (-0.94%)

08:21
09/19/19
09/19
08:21
09/19/19
08:21
Recommendations
General Mills analyst commentary  »

General Mills FY20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

08:21
09/19/19
09/19
08:21
09/19/19
08:21
Conference/Events
Milken Institute to hold a summit »

Asia Summit 2019: Asia at…

XLF

Financial Select Sector

$28.53

0.13 (0.46%)

08:21
09/19/19
09/19
08:21
09/19/19
08:21
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$121.67

0.09 (0.07%)

08:20
09/19/19
09/19
08:20
09/19/19
08:20
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.